2.91
price up icon4.68%   0.13
 
loading
前日終値:
$2.78
開ける:
$2.85
24時間の取引高:
895.06K
Relative Volume:
0.90
時価総額:
$485.68M
収益:
-
当期純損益:
$-54.70M
株価収益率:
-8.8182
EPS:
-0.33
ネットキャッシュフロー:
$-51.36M
1週間 パフォーマンス:
+3.19%
1か月 パフォーマンス:
+18.29%
6か月 パフォーマンス:
-31.37%
1年 パフォーマンス:
-41.57%
1日の値動き範囲:
Value
$2.72
$2.94
1週間の範囲:
Value
$2.61
$2.94
52週間の値動き範囲:
Value
$2.31
$5.34

Savara Inc Stock (SVRA) Company Profile

Name
名前
Savara Inc
Name
セクター
Healthcare (1166)
Name
電話
51285113796
Name
住所
6836 BEE CAVE ROAD, AUSTIN, TX
Name
職員
0
Name
Twitter
@SavaraPharma
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
SVRA's Discussions on Twitter

SVRA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SVRA
Savara Inc
2.91 485.68M 0 -54.70M -51.36M -0.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Savara Inc Stock (SVRA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-20 開始されました Wells Fargo Overweight
2024-11-13 ダウングレード Evercore ISI Outperform → In-line
2024-02-15 開始されました JMP Securities Mkt Outperform
2023-11-07 開始されました Guggenheim Buy
2023-05-16 アップグレード Jefferies Hold → Buy
2023-03-31 ダウングレード Jefferies Buy → Hold
2021-03-16 開始されました Piper Sandler Overweight
2021-03-15 開始されました Oppenheimer Outperform
2019-06-13 繰り返されました H.C. Wainwright Buy
2019-06-13 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2019-06-13 ダウングレード Ladenburg Thalmann Buy → Neutral
2018-08-13 再開されました ROTH Capital Neutral
2018-01-03 開始されました Ladenburg Thalmann Buy
2017-09-27 再開されました ROTH Capital Buy
2017-09-22 開始されました Jefferies Buy
2017-09-11 開始されました JMP Securities Mkt Outperform
すべてを表示

Savara Inc (SVRA) 最新ニュース

pulisher
Mar 28, 2025

Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Savara enters loan and security agreement with Hercules Capital - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Savara secures $200M loan to support respiratory drug launch - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Gets Up to $200 Million Loan From Hercules Capital - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Bluefield Daily Telegraph

Mar 26, 2025
pulisher
Mar 26, 2025

Major Financial Boost: Savara Lands $200M Debt Deal as FDA Decision Approaches - StockTitan

Mar 26, 2025
pulisher
Mar 26, 2025

Savara submits FDA application for aPAP therapy MOLBREEVI - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: First Treatment for Rare Lung Disease aPAP Heads to FDA Review - StockTitan

Mar 26, 2025
pulisher
Mar 26, 2025

Bank of New York Mellon Corp Purchases 17,870 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Mar 26, 2025
pulisher
Mar 24, 2025

Savara Inc (NASDAQ: SVRA) Stock: Investors Need To Know This - Stocks Register

Mar 24, 2025
pulisher
Mar 24, 2025

Victory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 24, 2025
pulisher
Mar 21, 2025

Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 20, 2025

Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 18, 2025

Savara Inc. to Present at Leerink Global Healthcare Conference - MSN

Mar 18, 2025
pulisher
Mar 17, 2025

Breakthrough Phase 3 Results: New Treatment Reduces Lung Procedures in Rare Disease Patients - StockTitan

Mar 17, 2025
pulisher
Mar 13, 2025

Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN

Mar 13, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register

Mar 08, 2025
pulisher
Mar 07, 2025

Savara, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell -March 06, 2025 at 08:55 am EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire

Mar 06, 2025
pulisher
Mar 06, 2025

Game-Changing Finger-Prick Test Could Transform Rare Lung Disease DiagnosisWhat Makes It Special? - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

Savara Announces Participation in the Leerink Global Healthcare Conference - Joplin Globe

Mar 03, 2025
pulisher
Mar 03, 2025

Rare Disease Biotech Savara Sets Key Investor Presentation at Leerink Conference - StockTitan

Mar 03, 2025
pulisher
Feb 27, 2025

Savara (SVRA) Expected to Announce Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Savara Insiders Lose Out As Stock Sinks To US$2.56 - Simply Wall St

Feb 26, 2025
pulisher
Feb 24, 2025

SVRA stock touches 52-week low at $2.58 amid market challenges - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

SVRA stock touches 52-week low at $2.58 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 23, 2025

Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $9.86 - Defense World

Feb 23, 2025
pulisher
Feb 18, 2025

Savara Inc. Awards Stock Options and RSUs to New Employees - MSN

Feb 18, 2025
pulisher
Feb 14, 2025

SVRASavara Inc Latest Stock News & Market Updates - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

Savara Announces New Employment Inducement Grant - Milton Daily Standard

Feb 14, 2025
pulisher
Feb 14, 2025

Savara's Latest Executive Compensation Package Revealed: Key Details on New Employee Stock Awards - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

A company insider recently sold 25,000 shares of Savara Inc [SVRA]. Should You Sale? - Knox Daily

Feb 14, 2025
pulisher
Feb 10, 2025

SG Americas Securities LLC Has $158,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World

Feb 10, 2025
pulisher
Feb 10, 2025

SVRA’s latest rating updates from top analysts. - Knox Daily

Feb 10, 2025
pulisher
Feb 08, 2025

Positive Signs As Multiple Insiders Buy Savara Stock - Yahoo Finance UK

Feb 08, 2025
pulisher
Feb 04, 2025

Investing in Savara Inc (SVRA) Is Getting More Attractive - Knox Daily

Feb 04, 2025
pulisher
Feb 03, 2025

Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN

Feb 03, 2025
pulisher
Feb 03, 2025

Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment - MSN

Feb 03, 2025

Savara Inc (SVRA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Savara Inc (SVRA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Pauls Matthew
CHIEF EXECUTIVE OFFICER
Dec 16 '24
Sale
3.31
54,702
180,828
1,536,379
Hawkins Richard J
Director
Dec 16 '24
Sale
3.32
8,000
26,569
67,241
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):